The Corporate Reputation of Pharma Survey Released

Article

In its ninth year, the survey includes the opinions of over 240 US-based patient groups on the performance of the pharmaceutical industry in 2021.

The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - USA Edition - The Views of 240 USA Patient Groups" report has been added to ResearchAndMarkets.com's offering.

The 240 US patient groups responding to the 2021 survey rated the pharma industry more favorably for corporate reputation than their predecessors in previous years. 67% of 2021's respondent patient groups stated that the industry had an "Excellent" or "Good" corporate reputation, against 57% saying the same in 2020.

The positivity of 2021's respondent patient groups appears to be largely driven by the pharma industry's response to the Covid-19 pandemic–specifically, the success some US companies have had at developing vaccines and treatments. In total, 81% of 2021's respondent patient groups stated that pharma was "Very effective" or "Effective" at providing support to patients during the pandemic, the same percentage as in 2020.

Continue reading this story here.

Related Videos
Jason Tate, FSP Talent Strategy Lead, PPD, part of Thermo Fisher Scientific
Related Content